Department of Pathology, M.D. Anderson International España, Madrid, Spain.
Clin Transl Oncol. 2010 Jun;12(6):431-6. doi: 10.1007/s12094-010-0530-8.
Surgery for rectal cancer continues to develop towards improving local control and overall survival, maintaining quality of life and preserving sphincter, genitourinary and sexual function. The multidisciplinary approach integrated in a team of different specialists ensures an individualised treatment for each patient with rectal cancer. Thus, the role of the pathologist has acquired an important relevance, not only in diagnosis, management and evaluation of the surgical specimen, but also for selection of the best adjuvant treatment. Parameters such as macroscopic quality of the mesorectum, status of the circumferential margin and lymph node harvest are considered basic criteria by current guidelines. Additionally, consistency in reporting based on the histologic classification proposed by the World Health Organization (WHO) is mandatory, along with inclusion into the pathologic report of current criteria for tumour node metastasis (TNM) staging, assessment of response to neoadjuvant chemoradiation therapy and clinically relevant molecular studies. Detection of defects in mismatch repair genes and mutational analysis of specific genes should be included as predictive markers for therapy.
直肠癌的外科治疗不断发展,旨在提高局部控制率和总体生存率,维持生活质量,保护肛门括约肌、泌尿生殖和性功能。不同专业人员组成的多学科团队的综合方法为每位直肠癌患者提供个体化治疗。因此,病理学家的作用变得非常重要,不仅在诊断、管理和评估手术标本中如此,在选择最佳辅助治疗方面也是如此。目前的指南将直肠系膜的大体质量、环周切缘状态和淋巴结采集数量等参数视为基本标准。此外,有必要根据世界卫生组织(WHO)提出的组织学分类进行一致的报告,并在病理报告中纳入肿瘤淋巴结转移(TNM)分期的现行标准、新辅助放化疗反应评估以及具有临床意义的分子研究。检测错配修复基因缺陷和特定基因的突变分析应作为预测治疗的标志物。